2015
DOI: 10.3109/0886022x.2014.991997
|View full text |Cite
|
Sign up to set email alerts
|

Pre-transplant low level HLA antibody shows a composite poor outcome in long-term outcome of renal transplant recipients

Abstract: To determine the significance of low-level DSA (donor specific antibody) in patients transplanted with negative cytotoxicity AHG (antihuman immunoglobulin) crossmatch, data from 279 patients who received a kidney transplant between July 1999 and March 2006 were collected. All kidney recipients received ABO-compatible donors. A poor outcome was defined as any one of the following: death, Cr42.0 mmol/L, occurrence of a rejection episode. Luminex Screening and Single Antigen assays from Tepnel Life Codes were use… Show more

Help me understand this report

Search citation statements

Order By: Relevance

Paper Sections

Select...
3
1
1

Citation Types

0
5
0

Year Published

2018
2018
2023
2023

Publication Types

Select...
6

Relationship

1
5

Authors

Journals

citations
Cited by 7 publications
(5 citation statements)
references
References 33 publications
0
5
0
Order By: Relevance
“…Therefore, in pretransplant period, determination of clinically relevant alloantibodies in sensitized patients and monitoring of antibody level during desensitization treatment would be needed. But in posttransplant period, although there are significant amount of evidences for the causal effect of DSA in graft rejection, the uniform consensus or guidelines for immune monitoring is hard to be set up partly because the lack of validated therapy once DSA are detected in a clinically and pathologically stable patient and vice versa (21)(22)(23)(24) and partly because the lack of data whether low level of DSA or anti-allelic DSA cause graft dysfunction (25,26) The study was performed by questionnaire surveys through emailing. The questionnaires were developed in two (Table 1).…”
Section: Introductionmentioning
confidence: 99%
“…Therefore, in pretransplant period, determination of clinically relevant alloantibodies in sensitized patients and monitoring of antibody level during desensitization treatment would be needed. But in posttransplant period, although there are significant amount of evidences for the causal effect of DSA in graft rejection, the uniform consensus or guidelines for immune monitoring is hard to be set up partly because the lack of validated therapy once DSA are detected in a clinically and pathologically stable patient and vice versa (21)(22)(23)(24) and partly because the lack of data whether low level of DSA or anti-allelic DSA cause graft dysfunction (25,26) The study was performed by questionnaire surveys through emailing. The questionnaires were developed in two (Table 1).…”
Section: Introductionmentioning
confidence: 99%
“…The full-text review was undertaken for 886 eligible articles; of these 78 articles discussed HLA incompatibility at the level of the antigen mismatch only, 64-141 whereas 163 articles assessed incompatibility by molecular genotyping, molecular mismatch analysis, and/or pretransplant DSA verification by solid-phase and/or by cell-based assays. 3,142-303 The Preferred Reporting Items for Systematic reviews and Meta-Analyses diagram outlining the article selection process is provided in Figure 1. 304…”
Section: Resultsmentioning
confidence: 99%
“…However, there are reports of patients with high-level DSA who remain free from rejection or allograft dysfunction [44,45]. Conversely, other studies have found low-level DSA associated with rejection, allograft dysfunction and decreased survival [31,46,47].…”
Section: Donor-specific Antibodies' Strength and Outcomesmentioning
confidence: 99%